In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMerieux, Genome to develop diagnostic products

Executive Summary

Genome Therapeutics and bioMerieux (diagnostic systems and reagents for infectious diseases and industrial applications) will develop, manufacture, and sell in vitro diagnostic products for human clinical and industrial applications. BioMerieux will pay a technology access fee up front, make a $3.75mm up-front equity investment in GT, fund research for at least four years, and pay sales royalties.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies